About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.

Dexmetomidine in Children Undergoing General Anaesthesia

Clinicaltrials.gov identifier NCT03923075

Recruitment Status Recruiting

First Posted April 22, 2019

Last update posted July 5, 2019

Study Description

Brief summary:

The effects of dexmedetomidine on the onset of both the general anaesthesia induction and the neuromuscular blockade in children of school age will be investigated. Ten minutes before the induction of general anaesthesia, the first group will receive continuous infusion of dexmedetomidine (DEX group), while the second group will receive normal saline (Placebo group).

  • Condition or Disease:Anesthesia
  • Intervention/Treatment: Drug: Dexmedetomidine
    Other: 0.9% saline
  • Phase: N/A
Detailed Description

Children 4 to 12 years old, ASA I-II, scheduled for elective minor or medium procedure under general anaesthesia will be included in the study, after written informed concern from their parents has been obtained. Participants will be randomly allocated according to the type of the solution infused 10 minutes before the induction of general anaesthesia into one of the following two groups using the closed envelop method. DEX group: patients will receive 0.5μcg/kg IV bolus of dexmedetomidine in 10 min, right before the induction of general anaesthesia. The concentration of dexmedetomidine solution is 0.2μcg/ml, (100μcg of dexmedetomidine are diluted in 50ml N/S 0.9%), which corresponds to volume (ml) calculated by the type: "body weight (Kg)/4 or body weight (Kg) X 0.25". Placebo group: patients will receive N/S 0.9% IV in 10 min, right before the induction of general anaesthesia. The volume infused (ml) is determined by the same type: "body weight (Kg)/4 or body weight (Kg) X 0.25". The above solutions will be prepared by the anaesthetist who will provide the anaesthesia and will not be known to the anaesthetist who will record the study's measurements. No premedication will be given. All children will receive the same anaesthesia induction scheme. Once the patients have entered the operating theater, standard monitoring will be applied (NIBP, ECG, SpO2) and an IV line will be inserted. Depth of anaesthesia and monitoring of neuromuscular blockade will be recorded by BIS and TOF, respectively. Afterwards continues infusion of dexmedetomidine or N/S 0.9% will be initiated, depending on the assigned group, for duration of 10 min. Right after the end of the infusion, we will proceed to the induction of anaesthesia with 3mg/kg of propofol and 2μcg/kg of fentanyl and when BIS<60 will be achieved, rocuronium will be administered at a dose of 0.7 mg/kg . Right afterwards, neuromuscular blockade will be estimated using the TOF acceleromyography (4 supramaximal twitches, 0.5sec interval in 2sec, frequency 2Hz, intensity 50mA). TOF will be repeated every 15sec. At the same time, ventilation of the patient will be supported with a bag and mask (Ο2 100%). When TOF=0 will be achieved, the patient will be intubated. After intubation, anaesthesia will be maintained with sevoflurane 1 MAC in 50% O2/Air. The intubation conditions will be estimated using the Viby-Mogensen score (scale of 5 parameters). Also, number of intubation attempts will be recorded. The study period is from "right before the start" of the dexmedetomidine or the N/S 0.9% infusion up to 5 min after the tracheal intubation. The following time points will be recorded: Start time of the IV infusion of dexmedetomidine or N/S 0.9% (tstart) End time of the IV infusion of dexmedetomidine or N/S 0.9% (tend) Time of propofol injection (tprop) Time of achieving BIS<60 (tBIS<60) Time from propofol injection to achieve BIS<60 (tprop - tBIS<60) in min Time of rocuronium injection (troc) Time of achieving TOF=0 (tTOF=0) Time from rocuronium injection to TOF=0 (troc - tTOF=0) in min Time that intubation performed (tintubation) Measurements Heart rate (HR), systolic arterial pressure (SAP), SpO2 and BIS will be recorded at the following time points: just before the start of infusion of dexmedetomidine or N/S 0.9% (tbaseline) and afterwards every 3 min during the infusion, as well as at the particular time points tend, tprop, tBIS<60, troc, tTOF=0, tintubation and 5 min after the intubation. Viby-Mogensen score and number of intubation attempts will also be recorded. During the study period, any adverse effects or incidences like respiratory depression during the 10 min infusion of the study solutions, bradycardia (defined as >20% reduction of HR from the baseline values or as HR<60bpm), hypotension (defined as >20mmHg reduction of SAP from the baseline values), allergic reactions, bronchospasm and laryngospasm will be recorded. In case of bradycardia or hypotension, IV atropine 0.02μcg/kg or ephedrine 1-2μcg/kg will be administered, respectively. In case of persistent bradycardia despite the use of atropine, dexmedetomidine infusion will be stopped and the child will be excluded from the study.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 60 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Parallel Assignment
  • Masking: Single (Outcomes Assessor)
  • Primary Purpose: Other
  • Official Title: The Effects of Dexmedetomidine on Induction of Anaesthesia and Onset of Neuromuscular Blockade in Children
  • Actual Study Start Date: May 2019
  • Estimated Primary Completion Date: January 2021
  • Estimated Study Completion Date: May 2021
Arms and interventions
Arm Intervention/treatment
Active Comparator: Dexmedetomidine
Drug: dexmedetomidine (Dexmed) solution(100μcg of dexmedetomidine in 50ml N/S 0.9%). given at a bolus dose of 0.5μcg/kg of the dexmedetomidine solution [that corresponds to the volume (ml) calculated by the type "body weight (Kg)/4 or body weight (Kg) X 0.25". THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY
Drug: Dexmedetomidine
INFUSION BEFORE INDUCTION OF ANAESTHESIA
Placebo Comparator: 0.9 % saline
Drug:0.9 % saline solution (Normal saline) given at a volume (ml) determined by the type: "body weight (Kg)/4 or body weight (Kg) X 0.25" THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY
Other: 0.9% saline
INFUSION BEFORE INDUCTION OF ANAESTHESIA
Outcome Measures
  • Primary Outcome Measures: 1. Onset of neuromuscular blockade [ Time Frame: Up to 5 minutes after the injection of rocuronium ]
    Neuromuscular blockade is estimated with TOF acceleromyography, while onset of neuromuscular blockaded is defined as the time needed to achieve TOF=0 after the injection of rocuronium.
  • Secondary Outcome Measures: 1. Onset of anaesthesia induction [ Time Frame: Up to 15 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively ]
    The depth of anaesthesia is monitored using the BIS device (range 0-100). Onset of anesthesia is defined as the time needed to achieve BIS value<60, after the injection of propofol.
  • 2. Number of participants who developed bradycardia [ Time Frame: Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively ]
    Bradycardia is defined as >20% reduction of HR from the baseline values or as HR<60bpm using ECG monitoring.
  • 3. Number of participants who developed hypotension [ Time Frame: Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively ]
    Hypotension is defined as >20mmHg reduction of SAP from the baseline values using noninvasive monitoring of arterial pressure
Eligibility Criteria
  • Ages Eligible for Study: 4 to 12 Years (Child)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- children underoing elective surgery under general anaesthsia

- age 4-12 years old

- ASA I-II

Exclusion Criteria:

- patient or parent refusal

- Mallampati score> 3

- BMI>35

- severe systemic cardiac disease

- neuromuscular disease

- recent respiratory infection

- drug allergy

Contacts and Locations
Contacts

Contact: Paraskevi K Matsota, Assoc Prof 6945544563 matsota@yahoo.gr

Contact: Paraskevi K Matsota 6945544563 matsota@yahoo.gr

Locations

Greece, Attiki
2nd Department of Anesthesiology, Attikon University Hospital
Athens

Sponsors and Collaborators

Attikon Hospital

Investigators

Study Chair: Georgia K Kostopanagiotou 2nd Department of Anaesthesiology, "Attikon" University Hospital

Principal Investigator: Paraskevi K Matsota 2nd Department of Anaesthesiology, "Attikon" University Hospital

More Information
  • Responsible Party: Attikon Hospital
  • ClinicalTrials.gov Identifier: NCT03923075 History of Changes
  • Other Study ID Numbers: DEXAINMBCH
  • First Posted: April 22, 2019 Key Record Dates
  • Last Update Posted: July 5, 2019
  • Last Verified: July 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Plan Description: restrictions due to regulation for personal data protection
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Attikon Hospital: TOF
    dexmedetomidine
    propofol
    rocuronium
    children